Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
about
Gout: optimizing treatment to achieve a disease cureInfusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapyThe management of goutInduced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipientsPOxylation as an alternative stealth coating for biomedical applications.A revised estimate of the burden of illness of gout.Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.Gout in 2013. Imaging, genetics and therapy: gout research continues apace.Advances in pharmacotherapy for the treatment of gout.Enzymes approved for human therapy: indications, mechanisms and adverse effects.The gouty tophus: a review.Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN).Current and future therapies for gout.Management of Gout and Hyperuricemia in CKD.Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout.Tophus resolution with pegloticase: a prospective dual-energy CT study.Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases.Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.[New drugs in rheumatology].Accuracy of the HumaSensplus point-of-care uric acid meter using capillary blood obtained by fingertip puncture.Impact of pegloticase on patient outcomes in refractory gout: current perspectives
P2860
Q26765550-65CBA695-16F8-4659-B550-CBCBE230C73DQ27000048-55330038-F12C-4512-A3F2-57803F901CA2Q28069759-74F2CDED-D509-441D-AA18-27EA6D3157EFQ33766720-D0549305-0D80-460D-94B9-E424F3AF9DB6Q33903653-5A6772C9-0D82-4FDD-A969-E748FE6CFE4AQ37502110-6F73F217-0B6B-4D59-9F88-766F8EDFFCC5Q37690972-FFEA6779-B86F-4E1E-9FF8-0C838CC3996CQ38166203-7D54519B-81E8-40E0-B64D-7277425DEC19Q38303416-E798B300-5472-4D36-988B-AEECF47EFA3BQ38342838-0F22D9E0-DFA0-4F42-9055-648BFE5F18D6Q38374318-F04EA92D-B59F-4E48-ABC9-EBC949705DF4Q38644685-8ECE3051-A41C-4E8A-B243-E3B9A0FDAF49Q38660829-84DC1681-4913-4BF9-B0EE-F843FED91364Q38812962-AB183606-DC9E-4E6E-8828-18A3153E6FC2Q38853112-1E7C8E31-ED7F-473E-8A65-44D4CACC8C15Q40089636-8409A944-7BDE-4944-8164-DCF74DBB5A32Q43209624-028CC852-E67F-4DF3-A83B-4C4996A4ACC1Q45025526-12119194-0A91-475B-8A45-6E1B90E5AB1AQ47104100-E83FF996-549C-4851-92AB-C19108C1FF35Q54374459-2756DD4C-E22B-4146-93C4-511EB2A06907Q55262503-2C0DECAE-CC4D-4E07-BCD5-D49E5EC04DC7Q58698860-53405AAC-96C5-46AE-B338-4CACFBE448A2
P2860
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
@en
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
@nl
type
label
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
@en
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
@nl
prefLabel
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
@en
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
@nl
P2093
P2860
P1476
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
@en
P2093
Aileen Dillon
Dinesh Khanna
Faith D Ottery
Herbert S B Baraf
Janitzia Vázquez-Mellado
John S Sundy
Michael A Becker
Robert A Yood
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-201795
P407
P577
2012-11-10T00:00:00Z